A Study Evaluating the Safety of LEO 90105 and Its Vehicle, After Multiple Administration on Intact Skin of Healthy Japanese Male Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01293383
Recruitment Status : Completed
First Posted : February 10, 2011
Last Update Posted : March 26, 2015
Quintiles, Inc.
Information provided by (Responsible Party):
LEO Pharma

Brief Summary:
The purpose of this trial is to to investigate the safety of LEO 90105 compared with its vehicle after multiple administration (twice daily, 5 days) in healthy Japanese male subjects.

Condition or disease Intervention/treatment Phase
Healthy Drug: LEO 90105 Phase 1

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 12 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Official Title: A Phase 1 Study Evaluating the Safety of LEO 90105 and Its Vehicle, After Multiple Administration on Intact Skin of Healthy Japanese Male Subjects. A Single Centre, Prospective, Randomised, Double-blinded, Vehicle-controlled Clinical Study
Study Start Date : March 2011
Actual Primary Completion Date : March 2011
Actual Study Completion Date : March 2011

Arm Intervention/treatment
LEO 90105 Drug: LEO 90105
Vehicle Drug: LEO 90105

Primary Outcome Measures :
  1. Skin irritation [ Time Frame: 6 days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   20 Years to 40 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy Japanese male subjects
  • Aged 20 to 40 years inclusive
  • Subjects without signs of skin irritation (erythema, dryness, roughness or scaling) on the test site
  • Subjects willing to follow the study procedures and complete the study
  • Subjects having understood and signed a written informed consent
  • Subjects without abnormal in physiological test and clinical test in screening, and also judged as possible to participant the study by investigators

Exclusion Criteria:

  • Subjects with Body mass Index (BMI ) (body weight(kg)/height (m)²) outside the range 18-25 kg/m2(18≤BMI<25)
  • Subjects with history of alcohol, chemical or drug abuse
  • Subjects with history of allergic reaction to any content of the study medication
  • Subjects with systemic or cutaneous disease that could in any way confound interpretation of the study results (e.g. atopic dermatitis, eczema, psoriasis)
  • Subjects with known sensitivity to any component of any of the formulations being tested
  • Subjects with known hepatic, renal or cardiac disorders
  • Subjects using systemic, locally injected or inhaled corticosteroids within 4 weeks of study start (Day 1)
  • Subjects using systemic vitamin D analogues,vitamin D or calcium supplements within 4 weeks of study start (Day 1)
  • Subjects using any drug (systemic or topical) within 2 weeks of study start (Day 1)
  • Subjects using non-marketed/other investigational products one month prior to or 5 half lives (for those the half life is longer than one month) and during the trial is not permitted
  • Subjects with any abnormality found at medical interview before administration of the test drug, which will affect the clinical study as judged by the investigator
  • Subjects with history of or active photo-induced or photo-aggravated disease (abnormal response to the sun light)
  • Subjects with exposure to excessive or chronic ultraviolet (UV) radiation i.e., sunbathing, tanning salon use, phototherapy) within four weeks prior to study start (Day 1) or planned during the study period
  • Subjects with scars, moles, sunburn, or other blemishes in the test area which would interfere with grading
  • Subjects whose partner wishes to become pregnant but is unwilling to use birth control during the study
  • Subjects with any condition which, in the opinion of the investigator, would place the subject at an unacceptable risk if he participated in the study
  • Subjects with any disease which are contradictions for treatment of the investigation products or for which treatment with the investigation products needs to be carefully considered (Subjects with any of the following conditions present on the area(s) to be treated with study medication: viral (e.g., herpes or varicella) lesions of the skin, fungal or bacterial skin infections, parasitic infections, skin manifestations in relation to syphilis or tuberculosis, rosacea, acne vulgaris, atrophic skin, striae atrophicae, fragility of skin veins, ichthyosis, acne rosacea, ulcers or wounds)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01293383

Hakata Clinic LTA Clinical Pharmacology Center
Fukuoka, Japan, 812-0025
Sponsors and Collaborators
LEO Pharma
Quintiles, Inc.
Principal Investigator: Masanari Shiramoto, MD., PhD Hakata Clinic LTA Clinical Pharmacology Center

Additional Information:
Responsible Party: LEO Pharma Identifier: NCT01293383     History of Changes
Other Study ID Numbers: MCB 0902
First Posted: February 10, 2011    Key Record Dates
Last Update Posted: March 26, 2015
Last Verified: March 2015